PML AS A POTENTIAL PREDICTIVE FACTOR OF EFFICACY OF OXALIPLATIN BASED FIRST LINE CHEMOTHERAPY IN COLORECTAL CANCER PATIENTS

被引：0
|
作者：
Vincenzi, B. [1 ]
Perrone, G. [1 ]
Santini, D. [1 ]
Loupakis, F. [2 ]
Graziano, F. [3 ]
Ruzzo, A. [4 ]
Venditti, O. [1 ]
OnettiMuda, A. [1 ]
Falcone, A. [2 ]
Tonini, G. [1 ]
机构：
[1] Univ Campus Biomed Rome, Rome, Italy
[2] Ist Toscano Tumori, Dept Oncol, Livomo, Italy
[3] Hosp Pesaro, Med Oncol Unit, Pesaro, Italy
[4] Univ Urbino, Dept Biomol Sci, I-61029 Urbino, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：67 / 67
页数：1
相关论文
共 50 条
  • [21] Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer
    E J Kap
    P Seibold
    S Richter
    D Scherer
    N Habermann
    Y Balavarca
    L Jansen
    N Becker
    K Pfütze
    O Popanda
    M Hoffmeister
    A Ulrich
    A Benner
    C M Ulrich
    B Burwinkel
    H Brenner
    J Chang-Claude
    The Pharmacogenomics Journal, 2015, 15 : 505 - 512
  • [22] Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer
    Kap, E. J.
    Seibold, P.
    Richter, S.
    Scherer, D.
    Habermann, N.
    Balavarca, Y.
    Jansen, L.
    Becker, N.
    Pfuetze, K.
    Popanda, O.
    Hoffmeister, M.
    Ulrich, A.
    Benner, A.
    Ulrich, C. M.
    Burwinkel, B.
    Brenner, H.
    Chang-Claude, J.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (06): : 505 - 512
  • [23] Efficacy of second line chemotherapy following first line triplet chemotherapy in advanced colorectal cancer (ACRC)
    Hakoun, A. M.
    Gad, A. M.
    Alzahrani, A.
    Aljubran, A.
    Bazarbashi, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] Efficacy of second-line chemotherapy after a first-line triplet in patients with metastatic colorectal cancer
    Bazarbashi, S.
    Hakoun, A. M.
    Gad, A. M.
    Elshenawy, M. A.
    Aljubran, A.
    Alzahrani, A. M.
    Eldali, A.
    CURRENT ONCOLOGY, 2019, 26 (01) : E24 - E29
  • [25] Chemotherapy efficacy in metastatic colorectal cancer (mCRC) patients treated with adjuvant or first-line FOLFOX-based chemotherapy.
    Samalin, Emmanuelle
    Tien Tuan Nguyen
    Thezenas, Simon
    Portales, Fabienne
    Mazard, Thibault
    Gourgou, Sophie
    Assenat, Eric
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Capecitabine combined with oxaliplatin (XELOX) as first-line chemotherapy in colorectal cancer with liver metastases
    Mahfouf, H.
    Djeddi, H.
    Belhadef, S.
    Bouzid, K.
    Bentabak, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] MIR-133A IS A PREDICTIVE BIOMARKER IN PATIENTS WITH METASTATIC COLORECTAL CANCER RECEIVING OXALIPLATIN-BASED CHEMOTHERAPY
    Ng, Simon S.
    Dong, Yujuan
    Leung, Wing Wa
    Ma, Brigette B.
    To, Ka Fai
    Sung, Joseph J.
    Yu, Jun
    GASTROENTEROLOGY, 2018, 154 (06) : S88 - S88
  • [28] The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
    Torben Frøstrup Hansen
    Flemming Brandt Sørensen
    Jan Lindebjerg
    Anders Jakobsen
    BMC Cancer, 12
  • [29] The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
    Hansen, Torben Frostrup
    Sorensen, Flemming Brandt
    Lindebjerg, Jan
    Jakobsen, Anders
    BMC CANCER, 2012, 12
  • [30] SAFETY AND EFFICACY OF OXALIPLATIN-BASED CHEMO-THERAPY IN THE FIRST LINE TREATMENT OF ELDERLY PATIENTS AFFECTED BY METASTATIC COLORECTAL CANCER
    Berretta, M.
    Nasti, G.
    De Diviitis, C.
    Divita, M.
    Fisichella, R.
    Sparta, D.
    Baresic, T.
    Ruffo, R.
    Urbani, M.
    Tirelli, U.
    WORLD CANCER RESEARCH JOURNAL, 2014, 1 (02)
12345